RIPK3 and plasma cell myeloma: Pharmacological inhibition of RIPK1 (Necrostatin-1 (Nec-1)) (Fig. 3.d.i-d.iii) and RIPK3 (GSK-872) (data not shown) failed to protect myeloma cells from Ad[CE1A]-induced cell death.